Jeremy L Davis1, Vitor Moutinho1, Katherine S Panageas2, Daniel G Coit1. 1. Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. 2. Department of Epidemiology & Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Abstract
AIM: Inflammatory biomarkers are associated with aging and disease-specific outcomes. We propose neutrophil-lymphocyte ratio (NLR) informs survival in a noncancer-bearing population. PATIENTS & METHODS: Retrospective cohort study of patients with a noncancer diagnosis. Calculation of NLR, ascertainment of age, gender, race, cardiovascular disease and diabetes status, and association with survival was determined. RESULTS: Elevated NLR was associated with worse overall survival, independent of age, gender and comorbid status. Overall survival was significantly worse for patients with high versus low NLR. CONCLUSION: Elevated NLR is associated with worse overall survival in noncancer patients. It remains unclear whether NLR reflects an acute inflammatory state, depressed host immune competence or both. NLR may simply be another predictor of survival, or potentially a modifiable risk factor.
AIM: Inflammatory biomarkers are associated with aging and disease-specific outcomes. We propose neutrophil-lymphocyte ratio (NLR) informs survival in a noncancer-bearing population. PATIENTS & METHODS: Retrospective cohort study of patients with a noncancer diagnosis. Calculation of NLR, ascertainment of age, gender, race, cardiovascular disease and diabetes status, and association with survival was determined. RESULTS: Elevated NLR was associated with worse overall survival, independent of age, gender and comorbid status. Overall survival was significantly worse for patients with high versus low NLR. CONCLUSION: Elevated NLR is associated with worse overall survival in noncancer patients. It remains unclear whether NLR reflects an acute inflammatory state, depressed host immune competence or both. NLR may simply be another predictor of survival, or potentially a modifiable risk factor.
Authors: Michael J Proctor; Donald C McMillan; Paul G Horgan; Colin D Fletcher; Dinesh Talwar; David S Morrison Journal: PLoS One Date: 2015-03-02 Impact factor: 3.240
Authors: Elizabeth Sapey; Hannah Greenwood; Georgia Walton; Elizabeth Mann; Alexander Love; Natasha Aaronson; Robert H Insall; Robert A Stockley; Janet M Lord Journal: Blood Date: 2013-11-04 Impact factor: 22.113
Authors: Edmund K Bartlett; Jessica R Flynn; Katherine S Panageas; Richard A Ferraro; Jessica M Sta Cruz; Michael A Postow; Daniel G Coit; Charlotte E Ariyan Journal: Cancer Date: 2019-10-04 Impact factor: 6.860
Authors: Michael R Cassidy; Rachel E Wolchok; Junting Zheng; Katherine S Panageas; Jedd D Wolchok; Daniel Coit; Michael A Postow; Charlotte Ariyan Journal: EBioMedicine Date: 2017-03-24 Impact factor: 8.143
Authors: Sarah J Neal Webb; Steven J Schapiro; Chet C Sherwood; Mary Ann Raghanti; William D Hopkins Journal: PLoS One Date: 2020-12-16 Impact factor: 3.240